Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippos Kesisoglou

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
AAPS Pharmscitech|September 12, 2013
Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidateFilippos Kesisoglou
Journal of Clinical Pharmacology|November 18, 2020
Can PBPK Modeling Streamline Food Effect Assessments?Filippos Kesisoglou
Journal of Pharmaceutical Sciences|December 15, 2016
The Role of Physiologically Based Oral Absorption Modelling in Formulation Development Under a Quality by Design ParadigmFilippos Kesisoglou
Journal of Pharmaceutical Sciences|August 30, 2017
Physiologically Based Oral Absorption Modelling to Study Gut-Level Drug InteractionsJohn Chung, Filippos Kesisoglou
Clinical Pharmacology and Therapeutics|November 21, 2018
Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand DrugsRajesh Krishna, Filippos Kesisoglou
Journal of Pharmaceutical Sciences|July 25, 2015
An Extrusion Spheronization Approach to Enable a High Drug Load Formulation of a Poorly Soluble Drug with a Low Melting SurfactantAditya Tatavarti, Filippos Kesisoglou
The AAPS Journal|May 24, 2015
Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design ParadigmFilippos Kesisoglou, Amitava Mitra
The AAPS Journal|November 13, 2008
Understanding the effect of API properties on bioavailability through absorption modelingFilippos Kesisoglou, Yunhui Wu
Molecular Pharmaceutics|July 13, 2013
Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product developmentAmitava Mitra, Filippos Kesisoglou
The AAPS Journal|June 28, 2012
Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compoundsFilippos Kesisoglou, Amitava Mitra
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
AAPS Pharmscitech|September 12, 2013
Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidateFilippos Kesisoglou
Journal of Clinical Pharmacology|November 18, 2020
Can PBPK Modeling Streamline Food Effect Assessments?Filippos Kesisoglou
Journal of Pharmaceutical Sciences|December 15, 2016
The Role of Physiologically Based Oral Absorption Modelling in Formulation Development Under a Quality by Design ParadigmFilippos Kesisoglou
Journal of Pharmaceutical Sciences|August 30, 2017
Physiologically Based Oral Absorption Modelling to Study Gut-Level Drug InteractionsJohn Chung, Filippos Kesisoglou
Clinical Pharmacology and Therapeutics|November 21, 2018
Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand DrugsRajesh Krishna, Filippos Kesisoglou
Journal of Pharmaceutical Sciences|July 25, 2015
An Extrusion Spheronization Approach to Enable a High Drug Load Formulation of a Poorly Soluble Drug with a Low Melting SurfactantAditya Tatavarti, Filippos Kesisoglou
The AAPS Journal|May 24, 2015
Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design ParadigmFilippos Kesisoglou, Amitava Mitra
The AAPS Journal|November 13, 2008
Understanding the effect of API properties on bioavailability through absorption modelingFilippos Kesisoglou, Yunhui Wu
Molecular Pharmaceutics|July 13, 2013
Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product developmentAmitava Mitra, Filippos Kesisoglou
The AAPS Journal|June 28, 2012
Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compoundsFilippos Kesisoglou, Amitava Mitra
Pageof 10